US3687808A
(en)
|
1969-08-14 |
1972-08-29 |
Univ Leland Stanford Junior |
Synthetic polynucleotides
|
US4469863A
(en)
|
1980-11-12 |
1984-09-04 |
Ts O Paul O P |
Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
|
US4554101A
(en)
|
1981-01-09 |
1985-11-19 |
New York Blood Center, Inc. |
Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
|
US5023243A
(en)
|
1981-10-23 |
1991-06-11 |
Molecular Biosystems, Inc. |
Oligonucleotide therapeutic agent and method of making same
|
US4476301A
(en)
|
1982-04-29 |
1984-10-09 |
Centre National De La Recherche Scientifique |
Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
|
JPS5927900A
(ja)
|
1982-08-09 |
1984-02-14 |
Wakunaga Seiyaku Kk |
固定化オリゴヌクレオチド
|
US4501729A
(en)
|
1982-12-13 |
1985-02-26 |
Research Corporation |
Aerosolized amiloride treatment of retained pulmonary secretions
|
FR2540122B1
(fr)
|
1983-01-27 |
1985-11-29 |
Centre Nat Rech Scient |
Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application
|
US4605735A
(en)
|
1983-02-14 |
1986-08-12 |
Wakunaga Seiyaku Kabushiki Kaisha |
Oligonucleotide derivatives
|
US4948882A
(en)
|
1983-02-22 |
1990-08-14 |
Syngene, Inc. |
Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
|
US4824941A
(en)
|
1983-03-10 |
1989-04-25 |
Julian Gordon |
Specific antibody to the native form of 2'5'-oligonucleotides, the method of preparation and the use as reagents in immunoassays or for binding 2'5'-oligonucleotides in biological systems
|
US4587044A
(en)
|
1983-09-01 |
1986-05-06 |
The Johns Hopkins University |
Linkage of proteins to nucleic acids
|
US5118802A
(en)
|
1983-12-20 |
1992-06-02 |
California Institute Of Technology |
DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside
|
US5550111A
(en)
|
1984-07-11 |
1996-08-27 |
Temple University-Of The Commonwealth System Of Higher Education |
Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
|
US5430136A
(en)
|
1984-10-16 |
1995-07-04 |
Chiron Corporation |
Oligonucleotides having selectably cleavable and/or abasic sites
|
US5367066A
(en)
|
1984-10-16 |
1994-11-22 |
Chiron Corporation |
Oligonucleotides with selectably cleavable and/or abasic sites
|
US5258506A
(en)
|
1984-10-16 |
1993-11-02 |
Chiron Corporation |
Photolabile reagents for incorporation into oligonucleotide chains
|
US4828979A
(en)
|
1984-11-08 |
1989-05-09 |
Life Technologies, Inc. |
Nucleotide analogs for nucleic acid labeling and detection
|
FR2575751B1
(fr)
|
1985-01-08 |
1987-04-03 |
Pasteur Institut |
Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
|
US5185444A
(en)
|
1985-03-15 |
1993-02-09 |
Anti-Gene Deveopment Group |
Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
|
US5166315A
(en)
|
1989-12-20 |
1992-11-24 |
Anti-Gene Development Group |
Sequence-specific binding polymers for duplex nucleic acids
|
US5405938A
(en)
|
1989-12-20 |
1995-04-11 |
Anti-Gene Development Group |
Sequence-specific binding polymers for duplex nucleic acids
|
US5235033A
(en)
|
1985-03-15 |
1993-08-10 |
Anti-Gene Development Group |
Alpha-morpholino ribonucleoside derivatives and polymers thereof
|
US5034506A
(en)
|
1985-03-15 |
1991-07-23 |
Anti-Gene Development Group |
Uncharged morpholino-based polymers having achiral intersubunit linkages
|
US4762779A
(en)
|
1985-06-13 |
1988-08-09 |
Amgen Inc. |
Compositions and methods for functionalizing nucleic acids
|
US4737323A
(en)
|
1986-02-13 |
1988-04-12 |
Liposome Technology, Inc. |
Liposome extrusion method
|
US5317098A
(en)
|
1986-03-17 |
1994-05-31 |
Hiroaki Shizuya |
Non-radioisotope tagging of fragments
|
JPS638396A
(ja)
|
1986-06-30 |
1988-01-14 |
Wakunaga Pharmaceut Co Ltd |
ポリ標識化オリゴヌクレオチド誘導体
|
EP0260032B1
(en)
|
1986-09-08 |
1994-01-26 |
Ajinomoto Co., Inc. |
Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers
|
US5219740A
(en)
|
1987-02-13 |
1993-06-15 |
Fred Hutchinson Cancer Research Center |
Retroviral gene transfer into diploid fibroblasts for gene therapy
|
US5276019A
(en)
|
1987-03-25 |
1994-01-04 |
The United States Of America As Represented By The Department Of Health And Human Services |
Inhibitors for replication of retroviruses and for the expression of oncogene products
|
US5264423A
(en)
|
1987-03-25 |
1993-11-23 |
The United States Of America As Represented By The Department Of Health And Human Services |
Inhibitors for replication of retroviruses and for the expression of oncogene products
|
US4904582A
(en)
|
1987-06-11 |
1990-02-27 |
Synthetic Genetics |
Novel amphiphilic nucleic acid conjugates
|
ATE113059T1
(de)
|
1987-06-24 |
1994-11-15 |
Florey Howard Inst |
Nukleosid-derivate.
|
US5585481A
(en)
|
1987-09-21 |
1996-12-17 |
Gen-Probe Incorporated |
Linking reagents for nucleotide probes
|
US5188897A
(en)
|
1987-10-22 |
1993-02-23 |
Temple University Of The Commonwealth System Of Higher Education |
Encapsulated 2',5'-phosphorothioate oligoadenylates
|
US4924624A
(en)
|
1987-10-22 |
1990-05-15 |
Temple University-Of The Commonwealth System Of Higher Education |
2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
|
US5525465A
(en)
|
1987-10-28 |
1996-06-11 |
Howard Florey Institute Of Experimental Physiology And Medicine |
Oligonucleotide-polyamide conjugates and methods of production and applications of the same
|
DE3738460A1
(de)
|
1987-11-12 |
1989-05-24 |
Max Planck Gesellschaft |
Modifizierte oligonukleotide
|
WO1989005358A1
(en)
|
1987-11-30 |
1989-06-15 |
University Of Iowa Research Foundation |
Dna and rna molecules stabilized by modifications of the 3'-terminal phosphodiester linkage and their use as nucleic acid probes and as therapeutic agents to block the expression of specifically targeted genes
|
US5403711A
(en)
|
1987-11-30 |
1995-04-04 |
University Of Iowa Research Foundation |
Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved
|
US5082830A
(en)
|
1988-02-26 |
1992-01-21 |
Enzo Biochem, Inc. |
End labeled nucleotide probe
|
JPH03503894A
(ja)
|
1988-03-25 |
1991-08-29 |
ユニバーシィティ オブ バージニア アランミ パテンツ ファウンデイション |
オリゴヌクレオチド n‐アルキルホスホラミデート
|
US5278302A
(en)
|
1988-05-26 |
1994-01-11 |
University Patents, Inc. |
Polynucleotide phosphorodithioates
|
US5109124A
(en)
|
1988-06-01 |
1992-04-28 |
Biogen, Inc. |
Nucleic acid probe linked to a label having a terminal cysteine
|
US5216141A
(en)
|
1988-06-06 |
1993-06-01 |
Benner Steven A |
Oligonucleotide analogs containing sulfur linkages
|
US5175273A
(en)
|
1988-07-01 |
1992-12-29 |
Genentech, Inc. |
Nucleic acid intercalating agents
|
US5262536A
(en)
|
1988-09-15 |
1993-11-16 |
E. I. Du Pont De Nemours And Company |
Reagents for the preparation of 5'-tagged oligonucleotides
|
US5512439A
(en)
|
1988-11-21 |
1996-04-30 |
Dynal As |
Oligonucleotide-linked magnetic particles and uses thereof
|
US5599923A
(en)
|
1989-03-06 |
1997-02-04 |
Board Of Regents, University Of Tx |
Texaphyrin metal complexes having improved functionalization
|
US5457183A
(en)
|
1989-03-06 |
1995-10-10 |
Board Of Regents, The University Of Texas System |
Hydroxylated texaphyrins
|
US5391723A
(en)
|
1989-05-31 |
1995-02-21 |
Neorx Corporation |
Oligonucleotide conjugates
|
US5256775A
(en)
|
1989-06-05 |
1993-10-26 |
Gilead Sciences, Inc. |
Exonuclease-resistant oligonucleotides
|
US4958013A
(en)
|
1989-06-06 |
1990-09-18 |
Northwestern University |
Cholesteryl modified oligonucleotides
|
US5451463A
(en)
|
1989-08-28 |
1995-09-19 |
Clontech Laboratories, Inc. |
Non-nucleoside 1,3-diol reagents for labeling synthetic oligonucleotides
|
US5134066A
(en)
|
1989-08-29 |
1992-07-28 |
Monsanto Company |
Improved probes using nucleosides containing 3-dezauracil analogs
|
US5254469A
(en)
|
1989-09-12 |
1993-10-19 |
Eastman Kodak Company |
Oligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction procedures
|
US5399676A
(en)
|
1989-10-23 |
1995-03-21 |
Gilead Sciences |
Oligonucleotides with inverted polarity
|
US5264564A
(en)
|
1989-10-24 |
1993-11-23 |
Gilead Sciences |
Oligonucleotide analogs with novel linkages
|
US5264562A
(en)
|
1989-10-24 |
1993-11-23 |
Gilead Sciences, Inc. |
Oligonucleotide analogs with novel linkages
|
US5292873A
(en)
|
1989-11-29 |
1994-03-08 |
The Research Foundation Of State University Of New York |
Nucleic acids labeled with naphthoquinone probe
|
US5177198A
(en)
|
1989-11-30 |
1993-01-05 |
University Of N.C. At Chapel Hill |
Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
|
US5130302A
(en)
|
1989-12-20 |
1992-07-14 |
Boron Bilogicals, Inc. |
Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
|
US5486603A
(en)
|
1990-01-08 |
1996-01-23 |
Gilead Sciences, Inc. |
Oligonucleotide having enhanced binding affinity
|
US5681941A
(en)
|
1990-01-11 |
1997-10-28 |
Isis Pharmaceuticals, Inc. |
Substituted purines and oligonucleotide cross-linking
|
US5459255A
(en)
|
1990-01-11 |
1995-10-17 |
Isis Pharmaceuticals, Inc. |
N-2 substituted purines
|
US5587470A
(en)
|
1990-01-11 |
1996-12-24 |
Isis Pharmaceuticals, Inc. |
3-deazapurines
|
US5578718A
(en)
|
1990-01-11 |
1996-11-26 |
Isis Pharmaceuticals, Inc. |
Thiol-derivatized nucleosides
|
US5623065A
(en)
|
1990-08-13 |
1997-04-22 |
Isis Pharmaceuticals, Inc. |
Gapped 2' modified oligonucleotides
|
US5587361A
(en)
|
1991-10-15 |
1996-12-24 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having phosphorothioate linkages of high chiral purity
|
US5220007A
(en)
|
1990-02-15 |
1993-06-15 |
The Worcester Foundation For Experimental Biology |
Method of site-specific alteration of RNA and production of encoded polypeptides
|
US5149797A
(en)
|
1990-02-15 |
1992-09-22 |
The Worcester Foundation For Experimental Biology |
Method of site-specific alteration of rna and production of encoded polypeptides
|
AU7579991A
(en)
|
1990-02-20 |
1991-09-18 |
Gilead Sciences, Inc. |
Pseudonucleosides and pseudonucleotides and their polymers
|
US5214136A
(en)
|
1990-02-20 |
1993-05-25 |
Gilead Sciences, Inc. |
Anthraquinone-derivatives oligonucleotides
|
US5321131A
(en)
|
1990-03-08 |
1994-06-14 |
Hybridon, Inc. |
Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
|
US5470967A
(en)
|
1990-04-10 |
1995-11-28 |
The Dupont Merck Pharmaceutical Company |
Oligonucleotide analogs with sulfamate linkages
|
EP0745689A3
(en)
|
1990-05-11 |
1996-12-11 |
Microprobe Corporation |
A dipstick for a nucleic acid hybridization assay
|
GB9011454D0
(en)
|
1990-05-22 |
1990-07-11 |
Medical Res Council |
Polynucleotide amplification
|
AU8284991A
(en)
|
1990-06-29 |
1992-01-23 |
Regents Of The University Of Michigan, The |
Neurofibromatosis gene
|
US5489677A
(en)
|
1990-07-27 |
1996-02-06 |
Isis Pharmaceuticals, Inc. |
Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
|
US5618704A
(en)
|
1990-07-27 |
1997-04-08 |
Isis Pharmacueticals, Inc. |
Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
|
US5688941A
(en)
|
1990-07-27 |
1997-11-18 |
Isis Pharmaceuticals, Inc. |
Methods of making conjugated 4' desmethyl nucleoside analog compounds
|
US5623070A
(en)
|
1990-07-27 |
1997-04-22 |
Isis Pharmaceuticals, Inc. |
Heteroatomic oligonucleoside linkages
|
US5602240A
(en)
|
1990-07-27 |
1997-02-11 |
Ciba Geigy Ag. |
Backbone modified oligonucleotide analogs
|
US5218105A
(en)
|
1990-07-27 |
1993-06-08 |
Isis Pharmaceuticals |
Polyamine conjugated oligonucleotides
|
US5610289A
(en)
|
1990-07-27 |
1997-03-11 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogues
|
US5677437A
(en)
|
1990-07-27 |
1997-10-14 |
Isis Pharmaceuticals, Inc. |
Heteroatomic oligonucleoside linkages
|
US5541307A
(en)
|
1990-07-27 |
1996-07-30 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogs and solid phase synthesis thereof
|
US5138045A
(en)
|
1990-07-27 |
1992-08-11 |
Isis Pharmaceuticals |
Polyamine conjugated oligonucleotides
|
US5608046A
(en)
|
1990-07-27 |
1997-03-04 |
Isis Pharmaceuticals, Inc. |
Conjugated 4'-desmethyl nucleoside analog compounds
|
DE69126530T2
(de)
|
1990-07-27 |
1998-02-05 |
Isis Pharmaceutical, Inc., Carlsbad, Calif. |
Nuklease resistente, pyrimidin modifizierte oligonukleotide, die die gen-expression detektieren und modulieren
|
US5245022A
(en)
|
1990-08-03 |
1993-09-14 |
Sterling Drug, Inc. |
Exonuclease resistant terminally substituted oligonucleotides
|
HU217036B
(hu)
|
1990-08-03 |
1999-11-29 |
Sanofi |
Eljárás génexpresszió gátlására alkalmas vegyületek előállítására
|
US5177196A
(en)
|
1990-08-16 |
1993-01-05 |
Microprobe Corporation |
Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof
|
US5512667A
(en)
|
1990-08-28 |
1996-04-30 |
Reed; Michael W. |
Trifunctional intermediates for preparing 3'-tailed oligonucleotides
|
US5214134A
(en)
|
1990-09-12 |
1993-05-25 |
Sterling Winthrop Inc. |
Process of linking nucleosides with a siloxane bridge
|
US5561225A
(en)
|
1990-09-19 |
1996-10-01 |
Southern Research Institute |
Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages
|
JPH06505704A
(ja)
|
1990-09-20 |
1994-06-30 |
ギリアド サイエンシズ,インコーポレイテッド |
改変ヌクレオシド間結合
|
US5432272A
(en)
|
1990-10-09 |
1995-07-11 |
Benner; Steven A. |
Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
|
JP3172178B2
(ja)
|
1990-11-08 |
2001-06-04 |
ハイブライドン インコーポレイテッド |
合成オリゴヌクレオチドに対する多重リポータ基の組込み
|
US5510473A
(en)
|
1990-11-09 |
1996-04-23 |
The United States Of American As Represented By The Secretary Of Health And Human Services |
Cloning of the recA gene from thermus aquaticus YT-1
|
US5714331A
(en)
|
1991-05-24 |
1998-02-03 |
Buchardt, Deceased; Ole |
Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
|
US5719262A
(en)
|
1993-11-22 |
1998-02-17 |
Buchardt, Deceased; Ole |
Peptide nucleic acids having amino acid side chains
|
US5371241A
(en)
|
1991-07-19 |
1994-12-06 |
Pharmacia P-L Biochemicals Inc. |
Fluorescein labelled phosphoramidites
|
US5571799A
(en)
|
1991-08-12 |
1996-11-05 |
Basco, Ltd. |
(2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
|
ATE239484T1
(de)
|
1991-10-24 |
2003-05-15 |
Isis Pharmaceuticals Inc |
Derivatisierte oligonukleotide mit verbessertem aufnahmevermögen
|
US5484908A
(en)
|
1991-11-26 |
1996-01-16 |
Gilead Sciences, Inc. |
Oligonucleotides containing 5-propynyl pyrimidines
|
US5700922A
(en)
|
1991-12-24 |
1997-12-23 |
Isis Pharmaceuticals, Inc. |
PNA-DNA-PNA chimeric macromolecules
|
US5595726A
(en)
|
1992-01-21 |
1997-01-21 |
Pharmacyclics, Inc. |
Chromophore probe for detection of nucleic acid
|
US5565552A
(en)
|
1992-01-21 |
1996-10-15 |
Pharmacyclics, Inc. |
Method of expanded porphyrin-oligonucleotide conjugate synthesis
|
GB9206016D0
(en)
|
1992-03-19 |
1992-04-29 |
Sandoz Ltd |
Improvements in or relating to organic compounds
|
US5633360A
(en)
|
1992-04-14 |
1997-05-27 |
Gilead Sciences, Inc. |
Oligonucleotide analogs capable of passive cell membrane permeation
|
US5434257A
(en)
|
1992-06-01 |
1995-07-18 |
Gilead Sciences, Inc. |
Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
|
AU4528493A
(en)
|
1992-06-04 |
1994-01-04 |
Regents Of The University Of California, The |
In vivo gene therapy with intron-free sequence of interest
|
US5272250A
(en)
|
1992-07-10 |
1993-12-21 |
Spielvogel Bernard F |
Boronated phosphoramidate compounds
|
US5652355A
(en)
|
1992-07-23 |
1997-07-29 |
Worcester Foundation For Experimental Biology |
Hybrid oligonucleotide phosphorothioates
|
US5478745A
(en)
|
1992-12-04 |
1995-12-26 |
University Of Pittsburgh |
Recombinant viral vector system
|
US5574142A
(en)
|
1992-12-15 |
1996-11-12 |
Microprobe Corporation |
Peptide linkers for improved oligonucleotide delivery
|
US5593972A
(en)
|
1993-01-26 |
1997-01-14 |
The Wistar Institute |
Genetic immunization
|
JP3701966B2
(ja)
|
1993-01-26 |
2005-10-05 |
ウェイナー,デービッド・ビー |
遺伝物質送達のための組成物および方法
|
US5476925A
(en)
|
1993-02-01 |
1995-12-19 |
Northwestern University |
Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
|
GB9304618D0
(en)
|
1993-03-06 |
1993-04-21 |
Ciba Geigy Ag |
Chemical compounds
|
CA2159629A1
(en)
|
1993-03-31 |
1994-10-13 |
Sanofi |
Oligonucleotides with amide linkages replacing phosphodiester linkages
|
US5502177A
(en)
|
1993-09-17 |
1996-03-26 |
Gilead Sciences, Inc. |
Pyrimidine derivatives for labeled binding partners
|
US5457187A
(en)
|
1993-12-08 |
1995-10-10 |
Board Of Regents University Of Nebraska |
Oligonucleotides containing 5-fluorouracil
|
DK0733059T3
(da)
|
1993-12-09 |
2000-10-16 |
Univ Jefferson |
Forbindelser og fremgangsmåder til site-rettede mutationer i eukaryote celler
|
US5596091A
(en)
|
1994-03-18 |
1997-01-21 |
The Regents Of The University Of California |
Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
|
US5625050A
(en)
|
1994-03-31 |
1997-04-29 |
Amgen Inc. |
Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
|
US5525711A
(en)
|
1994-05-18 |
1996-06-11 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Pteridine nucleotide analogs as fluorescent DNA probes
|
US5597696A
(en)
|
1994-07-18 |
1997-01-28 |
Becton Dickinson And Company |
Covalent cyanine dye oligonucleotide conjugates
|
US5580731A
(en)
|
1994-08-25 |
1996-12-03 |
Chiron Corporation |
N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
|
US5962428A
(en)
|
1995-03-30 |
1999-10-05 |
Apollon, Inc. |
Compositions and methods for delivery of genetic material
|
US5652356A
(en)
|
1995-08-17 |
1997-07-29 |
Hybridon, Inc. |
Inverted chimeric and hybrid oligonucleotides
|
DE19608753C1
(de)
|
1996-03-06 |
1997-06-26 |
Medigene Gmbh |
Transduktionssystem und seine Verwendung
|
JP3756313B2
(ja)
|
1997-03-07 |
2006-03-15 |
武 今西 |
新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
|
US6770748B2
(en)
|
1997-03-07 |
2004-08-03 |
Takeshi Imanishi |
Bicyclonucleoside and oligonucleotide analogue
|
GB9710807D0
(en)
|
1997-05-23 |
1997-07-23 |
Medical Res Council |
Nucleic acid binding proteins
|
GB9710809D0
(en)
|
1997-05-23 |
1997-07-23 |
Medical Res Council |
Nucleic acid binding proteins
|
US7572582B2
(en)
|
1997-09-12 |
2009-08-11 |
Exiqon A/S |
Oligonucleotide analogues
|
US6794499B2
(en)
|
1997-09-12 |
2004-09-21 |
Exiqon A/S |
Oligonucleotide analogues
|
CA2263784A1
(en)
|
1998-03-23 |
1999-09-23 |
Megabios Corporation |
Dual-tagged proteins and their uses
|
US6140081A
(en)
|
1998-10-16 |
2000-10-31 |
The Scripps Research Institute |
Zinc finger binding domains for GNN
|
WO2000028004A1
(en)
|
1998-11-10 |
2000-05-18 |
The University Of North Carolina At Chapel Hill |
Virus vectors and methods of making and administering the same
|
US6453242B1
(en)
|
1999-01-12 |
2002-09-17 |
Sangamo Biosciences, Inc. |
Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
|
US6534261B1
(en)
|
1999-01-12 |
2003-03-18 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
US7084125B2
(en)
|
1999-03-18 |
2006-08-01 |
Exiqon A/S |
Xylo-LNA analogues
|
US6734291B2
(en)
|
1999-03-24 |
2004-05-11 |
Exiqon A/S |
Synthesis of [2.2.1]bicyclo nucleosides
|
EP1178999B1
(en)
|
1999-05-04 |
2007-03-14 |
Santaris Pharma A/S |
L-ribo-lna analogues
|
US20040192593A1
(en)
|
1999-07-26 |
2004-09-30 |
Baylor College Of Medicine |
Protease resistant ti-growth hormone releasing hormone
|
US6287860B1
(en)
|
2000-01-20 |
2001-09-11 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of MEKK2 expression
|
AU2001253812A1
(en)
|
2000-04-28 |
2001-11-12 |
Genzyme Corporation |
In vivo loading of mhc
|
DE60126483T2
(de)
|
2000-04-28 |
2007-12-06 |
Sangamo BioSciences, Inc., Richmond |
Gezielte Modifikation der Chromatinstruktur
|
ES2505700T3
(es)
|
2000-06-01 |
2014-10-10 |
University Of North Carolina At Chapel Hill |
Vectores de parvovirus duplicados
|
JP2002060786A
(ja)
|
2000-08-23 |
2002-02-26 |
Kao Corp |
硬質表面用殺菌防汚剤
|
US7879540B1
(en)
|
2000-08-24 |
2011-02-01 |
Promega Corporation |
Synthetic nucleic acid molecule compositions and methods of preparation
|
WO2003016496A2
(en)
|
2001-08-20 |
2003-02-27 |
The Scripps Research Institute |
Zinc finger binding domains for cnn
|
AU2002334307A1
(en)
|
2001-09-04 |
2003-03-18 |
Exiqon A/S |
Novel lna compositions and uses thereof
|
WO2003072788A1
(en)
|
2002-02-21 |
2003-09-04 |
The Wistar Institute Of Anatomy And Biology |
Methods and compositions for reversibly controlling expression of target genes in cells
|
US7449561B1
(en)
|
2002-02-26 |
2008-11-11 |
City Of Hope |
Alterations in the dystrophin gene associated with sporadic dilated cardiomyopathy
|
US7074596B2
(en)
|
2002-03-25 |
2006-07-11 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Synthesis and use of anti-reverse mRNA cap analogues
|
EP2338478B1
(en)
|
2002-06-28 |
2014-07-23 |
Protiva Biotherapeutics Inc. |
Method for producing liposomes
|
WO2004041177A2
(en)
|
2002-11-04 |
2004-05-21 |
Advisys, Inc. |
Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells
|
US20070185042A1
(en)
|
2003-08-08 |
2007-08-09 |
The Brigham And Women's Hospital, Inc. President And Fellows Of Harvard College |
Sirna based methods for treating alzheimer's disease
|
CA2539439C
(en)
|
2003-09-19 |
2012-10-23 |
Sangamo Biosciences, Inc. |
Engineered zinc finger proteins for regulation of gene expression
|
US20070192880A1
(en)
|
2003-10-03 |
2007-08-16 |
University Of Rochester |
Horming response element binding transregulators
|
US8507277B2
(en)
|
2003-10-24 |
2013-08-13 |
Gencia Corporation |
Nonviral vectors for delivering polynucleotides
|
CA2569664C
(en)
|
2004-06-07 |
2013-07-16 |
Protiva Biotherapeutics, Inc. |
Lipid encapsulated interfering rna
|
WO2005120152A2
(en)
|
2004-06-07 |
2005-12-22 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods of use
|
US7728118B2
(en)
|
2004-09-17 |
2010-06-01 |
Promega Corporation |
Synthetic nucleic acid molecule compositions and methods of preparation
|
EP1937213B1
(en)
|
2005-07-27 |
2017-10-25 |
Protiva Biotherapeutics Inc. |
Systems and methods for manufacturing liposomes
|
BRPI0614716A2
(pt)
|
2005-08-05 |
2011-04-12 |
Univ Michigan State |
método para produção de um produto quìmico a partir da via c4 de a. succinogenes
|
US7943374B2
(en)
|
2005-08-21 |
2011-05-17 |
Markus Hildinger |
Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
|
HUE043492T2
(hu)
|
2005-08-23 |
2019-08-28 |
Univ Pennsylvania |
Módosított nukleozidokat tartalmazó RNS és eljárások az alkalmazására
|
EP2046806A4
(en)
|
2006-07-05 |
2009-10-21 |
Scripps Research Inst |
CHIMERIC RECOMBINASES WITH ZINC FINGERS OPTIMIZED FOR CATALYSIS BY DIRECT EVOLUTION
|
WO2008070859A2
(en)
|
2006-12-07 |
2008-06-12 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Treatment of skin conditions by dickkopf1 (dkk1)
|
US20090018031A1
(en)
|
2006-12-07 |
2009-01-15 |
Switchgear Genomics |
Transcriptional regulatory elements of biological pathways tools, and methods
|
US8048998B2
(en)
|
2007-01-19 |
2011-11-01 |
Exiqon A/S |
Mediated cellular delivery of LNA oligonucleotides
|
WO2008151631A2
(en)
|
2007-06-15 |
2008-12-18 |
Exiqon A/S |
Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis
|
ES2914775T3
(es)
|
2007-10-26 |
2022-06-16 |
Academisch Ziekenhuis Leiden |
Medios y métodos para contrarresta trastornos del músculo
|
US20100076057A1
(en)
|
2008-09-23 |
2010-03-25 |
Northwestern University |
TARGET DNA INTERFERENCE WITH crRNA
|
WO2010042877A1
(en)
|
2008-10-09 |
2010-04-15 |
Tekmira Pharmaceuticals Corporation |
Improved amino lipids and methods for the delivery of nucleic acids
|
ES2560281T3
(es)
|
2008-10-17 |
2016-02-18 |
Joule Unlimited Technologies, Inc. |
Producción de etanol por microorganismos
|
DK3133160T3
(en)
|
2008-10-24 |
2019-04-01 |
Sarepta Therapeutics Inc |
EXON SKIP COMPOSITIONS FOR DMD
|
WO2010075424A2
(en)
|
2008-12-22 |
2010-07-01 |
The Regents Of University Of California |
Compositions and methods for downregulating prokaryotic genes
|
EP2206723A1
(en)
|
2009-01-12 |
2010-07-14 |
Bonas, Ulla |
Modular DNA-binding domains
|
US20120207744A1
(en)
|
2009-03-19 |
2012-08-16 |
Mendlein John D |
Reprogramming compositions and methods of using the same
|
TR201811076T4
(tr)
|
2009-06-10 |
2018-08-27 |
Arbutus Biopharma Corp |
Geliştirilmiş lipit formulasyonu.
|
EP2281579A1
(en)
|
2009-08-05 |
2011-02-09 |
BioNTech AG |
Vaccine composition comprising 5'-Cap modified RNA
|
US8802437B2
(en)
|
2009-09-24 |
2014-08-12 |
Cellectis |
Meganuclease reagents of uses thereof for treating genetic diseases caused by frame shift/non sense mutations
|
DK2494039T3
(da)
|
2009-10-31 |
2019-08-19 |
Genesis Tech Limited |
Fremgangsmåder til reprogrammering af celler og anvendelser deraf
|
PT2816112T
(pt)
|
2009-12-10 |
2018-11-20 |
Univ Iowa State Res Found Inc |
Modificação do adn modificada pelo efector tal
|
EP2533629B1
(en)
|
2010-02-11 |
2018-11-28 |
Recombinetics, Inc. |
Methods and materials for producing transgenic artiodactyls
|
CA2798988C
(en)
|
2010-05-17 |
2020-03-10 |
Sangamo Biosciences, Inc. |
Tal-effector (tale) dna-binding polypeptides and uses thereof
|
IT1400425B1
(it)
|
2010-06-08 |
2013-05-31 |
Amsterdam Molecular Therapeutics Bv |
Modified snrnas for use in therapy.
|
EP2517731A1
(en)
|
2011-04-07 |
2012-10-31 |
Ludwig-Maximilians-Universität München |
Method of activating a target gene in a cell
|
US9540623B2
(en)
|
2011-07-08 |
2017-01-10 |
Cellectis |
Method for increasing the efficiency of double-strand-break induced mutagenesis
|
JP6144691B2
(ja)
|
2011-11-16 |
2017-06-07 |
サンガモ セラピューティクス, インコーポレイテッド |
修飾されたdna結合タンパク質およびその使用
|
US8450107B1
(en)
|
2011-11-30 |
2013-05-28 |
The Broad Institute Inc. |
Nucleotide-specific recognition sequences for designer TAL effectors
|
GB201122458D0
(en)
|
2011-12-30 |
2012-02-08 |
Univ Wageningen |
Modified cascade ribonucleoproteins and uses thereof
|
CN112251436A
(zh)
|
2012-01-27 |
2021-01-22 |
比奥马林技术公司 |
治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸
|
WO2013152220A2
(en)
|
2012-04-04 |
2013-10-10 |
Life Technologies Corporation |
Tal-effector assembly platform, customized services, kits and assays
|
WO2013163628A2
(en)
|
2012-04-27 |
2013-10-31 |
Duke University |
Genetic correction of mutated genes
|
US9738879B2
(en)
|
2012-04-27 |
2017-08-22 |
Duke University |
Genetic correction of mutated genes
|
ES2960803T3
(es)
|
2012-05-25 |
2024-03-06 |
Univ California |
Métodos y composiciones para la modificación de ADN diana dirigida por RNA y para la modulación de la transcripción dirigida por RNA
|
US9890364B2
(en)
|
2012-05-29 |
2018-02-13 |
The General Hospital Corporation |
TAL-Tet1 fusion proteins and methods of use thereof
|
PL3494997T3
(pl)
|
2012-07-25 |
2020-04-30 |
The Broad Institute, Inc. |
Indukowalne białka wiążące dna i narzędzia perturbacji genomu oraz ich zastosowania
|
US9567581B2
(en)
|
2012-08-07 |
2017-02-14 |
The General Hospital Corporation |
Selective reactivation of genes on the inactive X chromosome
|
WO2014059255A1
(en)
|
2012-10-12 |
2014-04-17 |
The General Hospital Corporation |
Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins
|
KR101656237B1
(ko)
|
2012-10-23 |
2016-09-12 |
주식회사 툴젠 |
표적 DNA에 특이적인 가이드 RNA 및 Cas 단백질을 암호화하는 핵산 또는 Cas 단백질을 포함하는, 표적 DNA를 절단하기 위한 조성물 및 이의 용도
|
CN104769112A
(zh)
|
2012-11-01 |
2015-07-08 |
菲克特生物科学股份有限公司 |
用于在细胞中表达蛋白质的方法和产品
|
US20140140969A1
(en)
|
2012-11-20 |
2014-05-22 |
Sangamo Biosciences, Inc. |
Methods and compositions for muscular dystrophies
|
KR102145760B1
(ko)
|
2012-12-06 |
2020-08-19 |
시그마-알드리치 컴퍼니., 엘엘씨 |
Crispr-기초된 유전체 변형과 조절
|
WO2014093479A1
(en)
|
2012-12-11 |
2014-06-19 |
Montana State University |
Crispr (clustered regularly interspaced short palindromic repeats) rna-guided control of gene regulation
|
CN105164264B
(zh)
|
2012-12-12 |
2021-05-07 |
布罗德研究所有限公司 |
用于序列操纵和治疗应用的系统、方法和组合物的递送、工程化和优化
|
EP2931892B1
(en)
|
2012-12-12 |
2018-09-12 |
The Broad Institute, Inc. |
Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
|
US20140310830A1
(en)
|
2012-12-12 |
2014-10-16 |
Feng Zhang |
CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
|
AU2013359123B2
(en)
|
2012-12-12 |
2016-07-14 |
Massachusetts Institute Of Technology |
Engineering of systems, methods and optimized guide compositions for sequence manipulation
|
EP2825654B1
(en)
|
2012-12-12 |
2017-04-26 |
The Broad Institute, Inc. |
Crispr-cas component systems, methods and compositions for sequence manipulation
|
DK2931891T3
(da)
|
2012-12-17 |
2019-08-19 |
Harvard College |
Rna-styret modificering af menneskelige genomer
|
EP2971041B1
(en)
|
2013-03-15 |
2018-11-28 |
The General Hospital Corporation |
Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing
|
US9506058B2
(en)
*
|
2013-03-15 |
2016-11-29 |
Sarepta Therapeutics, Inc. |
Compositions for treating muscular dystrophy
|
CA3159715A1
(en)
|
2013-03-15 |
2014-09-18 |
Edward J. Britt |
Energy conversion device and method for making and using same
|
EP2997146A4
(en)
|
2013-05-15 |
2017-04-26 |
Sangamo BioSciences, Inc. |
Methods and compositions for treatment of a genetic condition
|
US20140356956A1
(en)
|
2013-06-04 |
2014-12-04 |
President And Fellows Of Harvard College |
RNA-Guided Transcriptional Regulation
|
MY177814A
(en)
|
2013-06-04 |
2020-09-23 |
Harvard College |
Rna-guided transcriptional regulation
|
KR102733409B1
(ko)
|
2013-06-05 |
2024-11-21 |
듀크 유니버시티 |
Rna-가이드 유전자 편집 및 유전자 조절
|
JP6738729B2
(ja)
|
2013-06-17 |
2020-08-12 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
分裂終了細胞の疾患および障害をターゲティングおよびモデリングするための系、方法および組成物の送達、エンジニアリングおよび最適化
|
EP3011035B1
(en)
|
2013-06-17 |
2020-05-13 |
The Broad Institute, Inc. |
Assay for quantitative evaluation of target site cleavage by one or more crispr-cas guide sequences
|
AU2014281028B2
(en)
|
2013-06-17 |
2020-09-10 |
Massachusetts Institute Of Technology |
Delivery and use of the CRISPR-Cas systems, vectors and compositions for hepatic targeting and therapy
|
PT3019619T
(pt)
|
2013-07-11 |
2021-11-11 |
Modernatx Inc |
Composições que compreendem polinucleótidos sintéticos que codificam proteínas relacionadas com crispr e sgarn sintéticos e métodos de utilização
|
US10421957B2
(en)
|
2013-07-29 |
2019-09-24 |
Agilent Technologies, Inc. |
DNA assembly using an RNA-programmable nickase
|
TW201536329A
(zh)
|
2013-08-09 |
2015-10-01 |
Isis Pharmaceuticals Inc |
用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
|
WO2015021426A1
(en)
|
2013-08-09 |
2015-02-12 |
Sage Labs, Inc. |
A crispr/cas system-based novel fusion protein and its application in genome editing
|
WO2015030149A1
(ja)
|
2013-08-29 |
2015-03-05 |
国立大学法人鳥取大学 |
細胞のアンチエイジングに関連する生体分子群
|
US9340799B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
MRNA-sensing switchable gRNAs
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
US10822606B2
(en)
|
2013-09-27 |
2020-11-03 |
The Regents Of The University Of California |
Optimized small guide RNAs and methods of use
|
KR102380245B1
(ko)
|
2013-11-07 |
2022-03-30 |
에디타스 메디신, 인코포레이티드 |
지배적인 gRNA를 이용하는 CRISPR-관련 방법 및 조성물
|
WO2015089354A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders
|
AU2014361781B2
(en)
|
2013-12-12 |
2021-04-01 |
Massachusetts Institute Of Technology |
Delivery, use and therapeutic applications of the CRISPR -Cas systems and compositions for genome editing
|
AU2014361834B2
(en)
|
2013-12-12 |
2020-10-22 |
Massachusetts Institute Of Technology |
CRISPR-Cas systems and methods for altering expression of gene products, structural information and inducible modular Cas enzymes
|
US10752881B2
(en)
|
2014-01-29 |
2020-08-25 |
Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Trans-differentiation of differentiation cells
|
ES2745769T3
(es)
|
2014-03-10 |
2020-03-03 |
Editas Medicine Inc |
Procedimientos y composiciones relacionados con CRISPR/CAS para tratar la amaurosis congénita de Leber 10 (LCA10)
|
WO2015155686A2
(en)
|
2014-04-08 |
2015-10-15 |
North Carolina State University |
Methods and compositions for rna-directed repression of transcription using crispr-associated genes
|
US20170175128A1
(en)
|
2014-04-18 |
2017-06-22 |
Editas Medicine, Inc. |
Crispr-cas-related methods, compositions and components for cancer immunotherapy
|
SG10202002486QA
(en)
|
2014-06-16 |
2020-04-29 |
Univ Johns Hopkins |
Compositions and methods for the expression of crispr guide rnas using the h1 promoter
|
US11254933B2
(en)
|
2014-07-14 |
2022-02-22 |
The Regents Of The University Of California |
CRISPR/Cas transcriptional modulation
|
CA2954920A1
(en)
|
2014-07-14 |
2016-01-21 |
The Regents Of The University Of California |
A protein tagging system for in vivo single molecule imaging and control of gene transcription
|
WO2016022866A1
(en)
|
2014-08-07 |
2016-02-11 |
Agilent Technologies, Inc. |
Cis-blocked guide rna
|
CN106714845A
(zh)
|
2014-08-11 |
2017-05-24 |
得克萨斯州大学系统董事会 |
通过crispr/cas9介导的基因编辑预防肌营养不良
|
WO2016049258A2
(en)
|
2014-09-25 |
2016-03-31 |
The Broad Institute Inc. |
Functional screening with optimized functional crispr-cas systems
|
GB201418965D0
(es)
|
2014-10-24 |
2014-12-10 |
Ospedale San Raffaele And Fond Telethon |
|
MA40880A
(fr)
|
2014-10-30 |
2017-09-05 |
Temple Univ Of The Commonwealth |
Éradication guidée par l'arn du virus jc humain et d'autres polyomavirus
|
US11319555B2
(en)
|
2014-11-20 |
2022-05-03 |
Duke University |
Compositions, systems and methods for cell therapy
|
IL301900A
(en)
|
2014-11-21 |
2023-06-01 |
Regeneron Pharma |
Methods and compositions for targeted genetic modification using paired guide rnas
|
EP3985115A1
(en)
|
2014-12-12 |
2022-04-20 |
The Broad Institute, Inc. |
Protected guide rnas (pgrnas)
|
US10190106B2
(en)
|
2014-12-22 |
2019-01-29 |
Univesity Of Massachusetts |
Cas9-DNA targeting unit chimeras
|
WO2016114972A1
(en)
|
2015-01-12 |
2016-07-21 |
The Regents Of The University Of California |
Heterodimeric cas9 and methods of use thereof
|
JP6886404B2
(ja)
|
2015-01-30 |
2021-06-16 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California |
初代造血細胞におけるタンパク質送達
|
EP3256487A4
(en)
|
2015-02-09 |
2018-07-18 |
Duke University |
Compositions and methods for epigenome editing
|
US20160281166A1
(en)
|
2015-03-23 |
2016-09-29 |
Parabase Genomics, Inc. |
Methods and systems for screening diseases in subjects
|
WO2016161380A1
(en)
*
|
2015-04-01 |
2016-10-06 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating duchenne muscular dystrophy and becker muscular dystrophy
|
EP3286318A2
(en)
|
2015-04-22 |
2018-02-28 |
Mina Therapeutics Limited |
Sarna compositions and methods of use
|
SG11201708653RA
(en)
|
2015-04-24 |
2017-11-29 |
Editas Medicine Inc |
Evaluation of cas9 molecule/guide rna molecule complexes
|
WO2016187717A1
(en)
|
2015-05-26 |
2016-12-01 |
Exerkine Corporation |
Exosomes useful for genome editing
|
RU2752834C2
(ru)
|
2015-06-18 |
2021-08-09 |
Те Брод Инститьют, Инк. |
Мутации фермента crispr, уменьшающие нецелевые эффекты
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
AU2016299729B2
(en)
|
2015-07-24 |
2020-07-23 |
Basf Se |
Pyridine compounds useful for combating phytopathogenic fungi
|
US20200123533A1
(en)
|
2015-07-31 |
2020-04-23 |
The Trustees Of Columbia University In The City Of New York |
High-throughput strategy for dissecting mammalian genetic interactions
|
EP4177346A3
(en)
|
2015-08-25 |
2023-07-26 |
Duke University |
Compositions and methods of improving specificity in genomic engineering using rna-guided endonucleases
|
CA2998894A1
(en)
|
2015-09-18 |
2017-03-23 |
The Regents Of The University Of California |
Methods for autocatalytic genome editing and neutralizing autocatalytic genome editing and compositions thereof
|
CA2996982A1
(en)
|
2015-09-23 |
2017-03-30 |
Universite Laval |
Modification of the dystrophin gene and uses thereof
|
EP4089175A1
(en)
|
2015-10-13 |
2022-11-16 |
Duke University |
Genome engineering with type i crispr systems in eukaryotic cells
|
SG10202104041PA
(en)
|
2015-10-23 |
2021-06-29 |
Harvard College |
Nucleobase editors and uses thereof
|
CN108513546A
(zh)
|
2015-10-28 |
2018-09-07 |
克里斯珀医疗股份公司 |
用于治疗杜氏肌营养不良症的材料和方法
|
EP3368689B1
(en)
|
2015-10-28 |
2020-06-17 |
The Broad Institute, Inc. |
Composition for modulating immune responses by use of immune cell gene signature
|
WO2017081288A1
(en)
|
2015-11-11 |
2017-05-18 |
Lonza Ltd |
Crispr-associated (cas) proteins with reduced immunogenicity
|
WO2017083766A1
(en)
|
2015-11-13 |
2017-05-18 |
Massachusetts Institute Of Technology |
High-throughput crispr-based library screening
|
EA201891317A3
(ru)
|
2015-11-30 |
2019-04-30 |
Дьюк Юниверсити |
Терапевтические мишени для коррекции гена дистрофина человека с помощью редактирования генов и способы их применения
|
EA201891619A1
(ru)
|
2016-01-11 |
2019-02-28 |
Те Борд Оф Трастиз Оф Те Лилэнд Стэнфорд Джуниор Юниверсити |
Химерные белки и способы регулирования экспрессии генов
|
EP3199632A1
(en)
|
2016-01-26 |
2017-08-02 |
ACIB GmbH |
Temperature-inducible crispr/cas system
|
CA3048963A1
(en)
|
2016-02-11 |
2017-08-17 |
The Regents Of The University Of California |
Methods and compositions for modifying a mutant dystrophin gene in a cell's genome
|
WO2017165859A1
(en)
|
2016-03-24 |
2017-09-28 |
Research Institute At Nationwide Children's Hospital |
Modified viral capsid proteins
|
EP3443081A4
(en)
|
2016-04-13 |
2019-10-30 |
Duke University |
CRISPR / CAS9-BASED REPRESSORS FOR IN VIVO SHUT-OFF OF GEN-TARGETS AND METHOD OF USE
|
DK3442600T5
(da)
|
2016-04-15 |
2024-09-16 |
Res Inst Nationwide Childrens Hospital |
ADENOASSOCIERET VIRUSVEKTORFREMFØRING AF ß-SARCOGLYCAN OG MIKRORNA-29 OG BEHANDLING AF MUSKELDYSTROFI
|
SG10202009852PA
(en)
|
2016-04-15 |
2020-11-27 |
Univ Pennsylvania |
Novel aav8 mutant capsids and compositions containing same
|
WO2017193029A2
(en)
|
2016-05-05 |
2017-11-09 |
Duke University |
Crispr/cas-related methods and compositions for treating duchenne muscular dystrophy
|
WO2017201199A1
(en)
|
2016-05-17 |
2017-11-23 |
Duke University |
Compositions and methods for the treatment of prader-willi syndrome
|
US20170362635A1
(en)
|
2016-06-20 |
2017-12-21 |
University Of Washington |
Muscle-specific crispr/cas9 editing of genes
|
EP3478829A1
(en)
|
2016-06-29 |
2019-05-08 |
Crispr Therapeutics AG |
Materials and methods for treatment of myotonic dystrophy type 1 (dm1) and other related disorders
|
AU2017290231A1
(en)
|
2016-06-30 |
2019-02-07 |
Sarepta Therapeutics, Inc. |
Exon skipping oligomers for muscular dystrophy
|
AU2017295898B2
(en)
|
2016-07-15 |
2023-08-17 |
Salk Institute For Biological Studies |
Methods and compositions for genome editing in non-dividing cells
|
AU2017300272A1
(en)
|
2016-07-18 |
2019-01-31 |
Jaan Biotherapeutics, Llc |
Compositions and methods for treatment of cardiac diseases
|
EP3487523B1
(en)
|
2016-07-19 |
2023-09-06 |
Duke University |
Therapeutic applications of cpf1-based genome editing
|
US20190235624A1
(en)
|
2016-07-19 |
2019-08-01 |
Supereye, Inc. |
Systems and methods for predictive visual rendering
|
CA3032699A1
(en)
|
2016-08-03 |
2018-02-08 |
President And Fellows Of Harvard College |
Adenosine nucleobase editors and uses thereof
|
US11352647B2
(en)
|
2016-08-17 |
2022-06-07 |
The Broad Institute, Inc. |
Crispr enzymes and systems
|
EP3500675A4
(en)
|
2016-08-19 |
2020-01-29 |
Whitehead Institute for Biomedical Research |
Methods of editing dna methylation
|
CN109844123A
(zh)
|
2016-08-19 |
2019-06-04 |
株式会社图尔金 |
经人工操纵的血管生成调控系统
|
KR102594051B1
(ko)
|
2016-08-20 |
2023-10-26 |
아벨리노 랩 유에스에이, 인크. |
단일 가이드 RNA, CRISPR/Cas9 시스템, 및 이의 사용방법
|
SG11201903089RA
(en)
|
2016-10-14 |
2019-05-30 |
Harvard College |
Aav delivery of nucleobase editors
|
WO2018081504A1
(en)
|
2016-10-28 |
2018-05-03 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating herpes simplex virus
|
WO2018098480A1
(en)
|
2016-11-28 |
2018-05-31 |
The Board Of Regents Of The University Of Texas System |
Prevention of muscular dystrophy by crispr/cpf1-mediated gene editing
|
WO2018098587A1
(en)
|
2016-12-01 |
2018-06-07 |
UNIVERSITé LAVAL |
Crispr-based treatment of friedreich ataxia
|
CA3046220A1
(en)
|
2016-12-08 |
2018-06-14 |
The Board Of Regents Of The University Of Texas System |
Dmd reporter models containing humanized duschene muscular dystrophy mutations
|
JOP20190166A1
(ar)
|
2017-01-05 |
2019-07-02 |
Univ Texas |
استراتيجية مثلى من أجل تعديلات تخطي إكسون باستخدام crispr/cas9 مع متواليات توجيه ثلاثي
|
JP2018143239A
(ja)
|
2017-03-01 |
2018-09-20 |
エリクサジェン,エルエルシー. |
多能性幹細胞を所望の細胞型へ効率的に分化する方法
|
EP3589330A4
(en)
|
2017-03-03 |
2021-01-06 |
Flagship Pioneering Innovations V, Inc. |
METHODS AND SYSTEMS FOR THE MODIFICATION OF DNA
|
US10687520B2
(en)
|
2017-03-07 |
2020-06-23 |
The Board Of Regents Of The University Of Texas System |
Generation and correction of a humanized mouse model with a deletion of dystrophin exon 44
|
WO2018162702A1
(en)
|
2017-03-10 |
2018-09-13 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Nuclease fusions for enhancing genome editing by homology-directed transgene integration
|
JP2020511521A
(ja)
|
2017-03-23 |
2020-04-16 |
ディーエヌエーアールエックス |
in vivoでの核酸発現のためのシステム及び方法
|
US11680262B2
(en)
|
2017-03-30 |
2023-06-20 |
Kyoto University |
Method for inducing exon skipping by genome editing
|
JP2020516285A
(ja)
|
2017-04-12 |
2020-06-11 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
新規vi型crisprオルソログ及び系
|
US20180305719A1
(en)
|
2017-04-19 |
2018-10-25 |
The Board Of Trustees Of The University Of Illinois |
Vectors For Integration Of DNA Into Genomes And Methods For Altering Gene Expression And Interrogating Gene Function
|
WO2018208998A1
(en)
|
2017-05-10 |
2018-11-15 |
The Regents Of The University Of California |
Directed editing of cellular rna via nuclear delivery of crispr/cas9
|
EP3420811A1
(en)
|
2017-06-29 |
2019-01-02 |
Paris Sciences et Lettres - Quartier Latin |
Non-human model for neurofibromatosis type 1
|
US11441135B2
(en)
|
2017-07-07 |
2022-09-13 |
Toolgen Incorporated |
Target-specific CRISPR mutant
|
US11279765B2
(en)
|
2017-07-08 |
2022-03-22 |
The General Hospital Corporation |
Compositions and methods to improve anti-angiogenic therapy and immunotherapy
|
WO2019023291A2
(en)
|
2017-07-25 |
2019-01-31 |
Dana-Farber Cancer Institute, Inc. |
COMPOSITIONS AND METHODS FOR PRODUCTION AND DECODING OF GUIDE RNA LIBRARIES AND USES THEREOF
|
CN109295053B
(zh)
|
2017-07-25 |
2023-12-22 |
中国科学院上海营养与健康研究所 |
通过诱导剪接位点碱基突变或多聚嘧啶区碱基置换调控rna剪接的方法
|
EP3441461A1
(en)
|
2017-08-11 |
2019-02-13 |
Baylor College of Medicine |
Cd1d-restricted nkt cells as a platform for off-the-shelf cancer immunotherapy
|
US20200260698A1
(en)
|
2017-08-18 |
2020-08-20 |
The Board Of Regents Of The University Of Texas System |
Exon deletion correction of duchenne muscular dystrophy mutations in the dystrophin actin binding domain 1 using crispr genome editing
|
JP2020532504A
(ja)
|
2017-08-31 |
2020-11-12 |
サレプタ セラピューティクス, インコーポレイテッド |
筋ジストロフィーを処置するための方法
|
US11779653B2
(en)
|
2017-09-29 |
2023-10-10 |
The Regents Of The University Of California |
Multi-armed polyrotaxane platform for protected nucleic acid delivery
|
WO2019079514A1
(en)
|
2017-10-17 |
2019-04-25 |
Massachusetts Institute Of Technology |
METHODS OF FUNCTIONAL DISSECTION AT THE GENOME SCALE AT HIGH RESOLUTION OF TRANSCRIPTIONAL REGULATORY REGIONS
|
SG11202002186VA
(en)
|
2017-10-19 |
2020-05-28 |
Curevac Ag |
Novel artificial nucleic acid molecules
|
US20210268667A1
(en)
|
2017-10-23 |
2021-09-02 |
Stoke Therapeutics, Inc. |
Antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseases
|
MA50578A
(fr)
|
2017-11-09 |
2021-09-15 |
Vertex Pharma |
Systèmes crispr/cas pour le traitement de dmd
|
CA3084810A1
(en)
|
2017-12-08 |
2019-06-13 |
University Of Connecticut |
Compositions and methods for treating disorders of genomic imprinting
|
EP3723774A4
(en)
|
2017-12-15 |
2021-09-08 |
The Board of Trustees of the Leland Stanford Junior University |
COMPOSITIONS AND METHODS FOR INHIBITING T-LYMPHOCYTE DEPLETION
|
WO2019123014A1
(en)
|
2017-12-22 |
2019-06-27 |
G+Flas Life Sciences |
Chimeric genome engineering molecules and methods
|
KR20200104318A
(ko)
|
2017-12-28 |
2020-09-03 |
고쿠리츠 다이가쿠 호진 교토 다이가쿠 |
표적 유전자 개변용 조성물
|
WO2019136216A1
(en)
|
2018-01-05 |
2019-07-11 |
The Board Of Regents Of The University Of Texas System |
Therapeutic crispr/cas9 compositions and methods of use
|
EP3755792A4
(en)
|
2018-02-23 |
2021-12-08 |
Pioneer Hi-Bred International, Inc. |
NEW CASE ORTHOLOGISTS9
|
US20210254049A1
(en)
|
2018-04-20 |
2021-08-19 |
Cellino Biotech, Inc. |
Directed cell fate specification and targeted maturation
|
CA3099332A1
(en)
|
2018-05-03 |
2019-11-07 |
President And Fellows Of Harvard College |
In vivo homology directed repair in heart, skeletal muscle, and muscle stem cells
|
CA3101477A1
(en)
|
2018-05-30 |
2019-12-05 |
M2X2 Therapeutics, Inc. |
Cell therapy
|
WO2020018918A1
(en)
|
2018-07-19 |
2020-01-23 |
The Board Of Trustees Of The University Of Illinois |
Methods for exon skipping and gene knockout using base editors
|
EP3897748A4
(en)
|
2018-12-20 |
2023-01-25 |
Ohio State Innovation Foundation |
COMPOSITIONS AND METHODS FOR REPROGRAMMING DISEASE MUSCLE SKELETAL CELLS
|
BR102019009665A2
(pt)
|
2018-12-21 |
2022-02-08 |
Jacques P. Tremblay |
Modificação da proteína precursora beta amiloide (app) através da edição de base usando o sistema crispr/cas9
|
EP3921417A4
(en)
|
2019-02-04 |
2022-11-09 |
The General Hospital Corporation |
ADENINE DNA BASE EDITOR VARIANTS WITH REDUCED OFF-TARGET RNA EDITING
|
EP3924481A4
(en)
|
2019-02-13 |
2023-01-25 |
Beam Therapeutics Inc. |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
|
WO2020210776A1
(en)
|
2019-04-12 |
2020-10-15 |
Duke University |
Crispr/cas-based base editing composition for restoring dystrophin function
|
AR118670A1
(es)
|
2019-04-14 |
2021-10-20 |
Univ Duke |
Eliminación mediada por vectores aav de grandes puntos de mutación para el tratamiento de la distrofia muscular de duchenne
|
AR118668A1
(es)
|
2019-04-14 |
2021-10-20 |
Univ Duke |
Composiciones para editar genoma a base de crispr / cas para restaurar la función de distrofina
|
WO2020257665A1
(en)
|
2019-06-20 |
2020-12-24 |
Celgene Corporation |
Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome
|
WO2021026516A1
(en)
|
2019-08-08 |
2021-02-11 |
Duke University |
High-throughput screening platform for engineering next-generation gene therapy vectors
|
KR20220047623A
(ko)
|
2019-08-19 |
2022-04-18 |
듀크 유니버시티 |
세포 유형 운명 특정화의 조절인자를 확인하기 위한 조성물 및 방법
|
CN114599403A
(zh)
|
2019-08-19 |
2022-06-07 |
杜克大学 |
通过基于crispr/cas9的转录激活物获得的骨骼肌成肌细胞祖细胞谱系的特化
|
WO2021055956A1
(en)
|
2019-09-20 |
2021-03-25 |
The Uab Research Foundation |
Methods of treatment of neurofibromatosis type 1 (nf1) and nf1-mediated conditions and compositions for use in such methods
|
WO2021067878A1
(en)
|
2019-10-02 |
2021-04-08 |
Duke University |
Epigenetic modulation of genomic targets to control expression of pws-associated genes
|
AR122347A1
(es)
|
2019-12-03 |
2022-09-07 |
Univ Duke |
Sistemas y métodos para la distribución de maquinaria de edición génica por nanopartículas lipídicas
|
US20230349888A1
(en)
|
2020-04-27 |
2023-11-02 |
Duke University |
A high-throughput screening method to discover optimal grna pairs for crispr-mediated exon deletion
|
WO2021222314A1
(en)
|
2020-04-27 |
2021-11-04 |
Duke University |
Gene editing of satellite cells in vivo using aav vectors encoding muscle-specific promoters
|
WO2021222328A1
(en)
|
2020-04-27 |
2021-11-04 |
Duke University |
Targeted genomic integration to restore neurofibromin coding sequence in neurofibromatosis type 1 (nf1)
|
EP4200406A1
(en)
|
2020-08-21 |
2023-06-28 |
Julius-Maximilians-Universität Würzburg |
Modified lymphocytes
|
US20230383297A1
(en)
|
2020-10-09 |
2023-11-30 |
Duke University |
Novel targets for reactivation of prader-willi syndrome-associated genes
|
JP2023545132A
(ja)
|
2020-10-12 |
2023-10-26 |
デューク ユニバーシティ |
ジストロフィン機能を修復するためのcrispr/casをベースにした塩基編集組成物
|
EP4232152A1
(en)
|
2020-10-21 |
2023-08-30 |
Duke University |
Dual aav vector-mediated deletion of large mutational hotspot for treatment of duchenne muscular dystrophy
|
IL302879A
(en)
|
2020-11-11 |
2023-07-01 |
Univ Columbia |
Multiplex epigenome editing
|
WO2022104159A1
(en)
|
2020-11-13 |
2022-05-19 |
Duke University |
Targeted gene regulation of human immune cells with crispr-cas systems
|
WO2022133062A1
(en)
|
2020-12-16 |
2022-06-23 |
Epicrispr Biotechnologies, Inc. |
Systems and methods for engineering characteristics of a cell
|
US20240141341A1
(en)
|
2021-03-01 |
2024-05-02 |
Duke University |
Systems and methods for genome-wide annotation of gene regulatory elements linked to cell fitness
|
US20240254483A1
(en)
|
2021-07-30 |
2024-08-01 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of frataxin (fxn)
|
AU2022318664A1
(en)
|
2021-07-30 |
2024-02-29 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
|
WO2023137472A2
(en)
|
2022-01-14 |
2023-07-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression
|
WO2023137471A1
(en)
|
2022-01-14 |
2023-07-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
|
US20240058425A1
(en)
|
2022-03-08 |
2024-02-22 |
Duke University |
Systems and methods for genome-wide annotation of gene regulatory elements linked to cell fitness
|
WO2023200998A2
(en)
|
2022-04-13 |
2023-10-19 |
Duke University |
Effector domains for crispr-cas systems
|
WO2023250511A2
(en)
|
2022-06-24 |
2023-12-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression
|
WO2024015881A2
(en)
|
2022-07-12 |
2024-01-18 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for targeted transcriptional activation
|
WO2024040253A1
(en)
|
2022-08-18 |
2024-02-22 |
Duke University |
Epigenetic modulation of genomic targets to control expression of pws-associated genes
|
TW202426641A
(zh)
|
2022-08-19 |
2024-07-01 |
美商圖恩療法股份有限公司 |
以靶向基因抑制來調節b型肝炎病毒之組合物、系統和方法
|
WO2024064642A2
(en)
|
2022-09-19 |
2024-03-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for modulating t cell function
|